Combination Trial of Patupilone and Carboplatin in Adult Patients With Advanced Solid Tumors

This study has been completed.
Information provided by:
Novartis Identifier:
First received: January 24, 2007
Last updated: March 24, 2011
Last verified: March 2011
This study will evaluate the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of patupilone combined with carboplatin in adult patients with advanced solid tumors who progressed despite standard therapy or for whom no standard therapy exists or who might benefit from treatment with carboplatin

Condition Intervention Phase
Advanced Solid Tumors
Drug: Patupilone
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase Ib, Multicenter, Open-label, Dose-finding Study of Patupilone Administered Intravenously Every 3 Weeks in Combination With Carboplatin AUC 6 in Adult Patients With Advanced Solid Tumors

Resource links provided by NLM:

Further study details as provided by Novartis:

Primary Outcome Measures:
  • Maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of patupilone in combination with carboplatin (AUC 6) [ Time Frame: Every 3 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Safety of patupilone combined with carboplatin assessed by adverse events, serious adverse events, laboratory values and physical examinations [ Time Frame: Every 6 weeks ] [ Designated as safety issue: Yes ]
  • Overall response rate (complete and partial response; CR + PR) according to RECIST (response evaluation criteria in solid tumors) [ Time Frame: Every 6 weeks ] [ Designated as safety issue: No ]
  • Time to progression (TTP), duration of overall response, duration of stable disease and time to overall response [ Time Frame: Every 6 weeks ] [ Designated as safety issue: No ]
  • Pharmacokinetic profile of patupilone combined with carboplatin [ Time Frame: First 6 weeks (cycle 1 & 2 only) ] [ Designated as safety issue: No ]
  • Relationship between pharmacokinetics and clinical outcome [ Time Frame: Every 6 weeks during cycle 1 & cycle 2 ] [ Designated as safety issue: No ]

Enrollment: 48
Study Start Date: August 2006
Primary Completion Date: August 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Patupilone only
Cycle 1 patupilone alone Cycle 2 and onward patupilone and carboplatin
Drug: Patupilone
Active Comparator: Carboplatin alone
Cycle 1 Carboplatin alone Cycle 2 and onward patuilone and carboplatin
Drug: Patupilone


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Histologically or cytologically confirmed advanced solid tumors who have progressed despite standard therapy, or for whom no standard therapy exists, or who might benefit from treatment with carboplatin
  • A minimum of 4 weeks since the last treatment with chemotherapy
  • WHO Performance Status 0 (able to carry out all normal activity without restriction) or 1 (restricted in physically strenuous activity but ambulatory and able to carry out work)
  • Age ≥ 18
  • Adequate hematological parameters
  • No major impairment of renal or hepatic function
  • Written informed consent obtained

Exclusion criteria:

  • Major surgery less than 4 weeks prior to study entry and/or not fully recovered from surgery
  • Chemotherapy or investigational compound less than 4 weeks prior to study entry, or planned while participating in the study
  • Prior administration of an epothilone
  • Hypersensitivity to carboplatin. Patients resistant to carboplatin are not recommended to enter the trial
  • Radiotherapy (RT) less than 4 weeks prior to study entry (except for palliative therapy of distant metastases), or planned RT while participating in the study
  • Diarrhea within 7 days prior to start of treatment. Unresolved bowel obstruction
  • Peripheral neuropathy > Grade 1 (mild)
  • Symptomatic brain metastases
  • Colostomy

Other protocol-defined inclusion/exclusion criteria may apply

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00426582

United States, Connecticut
Norwalk Hospital
Norwalk, Connecticut, United States, 06856
United States, Maryland
Associates in Oncology
Rockville, Maryland, United States, 20850
United States, Michigan
Wertz Clinical Cancer Center (Wayne State University)
Detroit, Michigan, United States, 48201
United States, Missouri
Siteman Cancer Center (Washington University School of Medicine)
St. Louis, Missouri, United States, 63110-1093
United States, New Mexico
Cancer Research and Treatment Center (University of New Mexico)
Albuquerque, New Mexico, United States, 87131
Sponsors and Collaborators
Novartis Pharmaceuticals
Study Director: Novartis Pharmaceuticals Novartis Pharmeceuticals
  More Information

Responsible Party: External Affairs, Novartis Pharmaceuticals Identifier: NCT00426582     History of Changes
Other Study ID Numbers: CEPO906A2105 
Study First Received: January 24, 2007
Last Updated: March 24, 2011
Health Authority: United States: Food and Drug Administration
France: Agence Francaise de Securite Sanitaire des Aliments (AFSSA; Agency for Food Safety)

Keywords provided by Novartis:
maximum tolerated dose
dose-limiting toxicity

Additional relevant MeSH terms:
Epothilone B
Antimitotic Agents
Antineoplastic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Tubulin Modulators processed this record on May 30, 2016